Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration for ALN-AT3, an RNAi Therapeutic for the Treatment of Hemophilia

Published August 14, 2013

Alnylam Receives Orphan Drug Designation from U.S. Food & Drug Administration for ALN-AT3, an RNAi Therapeutic for the Treatment of Hemophilia
Alnylam plans to file an investigational new drug (IND) application for ALN-AT3 in the fourth quarter of 2013 and initiate a Phase I clinical … for the filing of a new drug application (NDA) with a focused patient database and possible … drug rehab – Bing News

Rehab racket: Frauds, felons and fakes
The populous Los Angeles region is one of the nation’s top hot spots for health care fraud, and former state officials agree it is also ground zero for the rehab racket. Related: CNN/CIR probe spurs hearings on alleged fraud Drug Medi-Cal paid … drug rehab – Bing News